🇺🇸 pulmonary surfactant in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 22

Most-reported reactions

1. Disseminated Intravascular Coagulation — 3 reports (13.64%)
2. Neonatal Hypoxia — 3 reports (13.64%)
3. Atelectasis — 2 reports (9.09%)
4. Bradycardia — 2 reports (9.09%)
5. Bronchitis — 2 reports (9.09%)
6. Bronchospasm — 2 reports (9.09%)
7. Candida Infection — 2 reports (9.09%)
8. Central Venous Catheterisation — 2 reports (9.09%)
9. Condition Aggravated — 2 reports (9.09%)
10. Cyanosis — 2 reports (9.09%)

Source database →

Frequently asked questions

Is pulmonary surfactant approved in United States?

pulmonary surfactant does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for pulmonary surfactant in United States?

National Heart, Lung, and Blood Institute (NHLBI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.